Shanghai OPM Biosciences Co Ltd
SSE:688293
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanghai OPM Biosciences Co Ltd
Cash from Operating Activities
Shanghai OPM Biosciences Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai OPM Biosciences Co Ltd
SSE:688293
|
Cash from Operating Activities
¥69.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Cash from Operating Activities
¥13.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Operating Activities
¥1.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Cash from Operating Activities
¥53m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cash from Operating Activities
-¥408.6m
|
CAGR 3-Years
31%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Cash from Operating Activities
-¥180.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai OPM Biosciences Co Ltd
Glance View
Shanghai OPM Biosciences Co. Ltd. engages in the cell culture products and services. The company is headquartered in Shanghai, Shanghai and currently employs 261 full-time employees. The company went IPO on 2022-09-02. The firm's cell culture medium products are widely used in the manufacturing of protein, antibiotics, vaccine, cell therapy products, gene therapy products, and other biological products. The firm's contract development and manufacturing organization (CDMO) service platform provides comprehensive services covering antibody engineering humanized screening, cell strain cultivation, process development, pilot scale production, and clinical-stage sample production. The firm conducts businesses both in the domestic market and overseas markets.
See Also
What is Shanghai OPM Biosciences Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
69.2m
CNY
Based on the financial report for Dec 31, 2024, Shanghai OPM Biosciences Co Ltd's Cash from Operating Activities amounts to 69.2m CNY.
What is Shanghai OPM Biosciences Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
32%
Over the last year, the Cash from Operating Activities growth was 19%. The average annual Cash from Operating Activities growth rates for Shanghai OPM Biosciences Co Ltd have been -15% over the past three years , 32% over the past five years .
